This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Patients could also suffer surgical morbidity or mortality associated with treatment. Patients moved to the "alive_notreat" state when they had either been found to be "untreatable" (i.e. to have more metastases than the threshold for treatment in the strategy being considered), or when they had had the maximum allowable number of treatments for the strategy under consideration. At the end of each cycle, patients returned to one of the three model states and this process continued until all patients in the initial cohort reach the "dead" state, at which point the simulation was terminated. The cycle length was one month and the time horizon was the patient's lifetime. The structure of the model and a full description of the model assumptions were given.
Outcomes assessed in the review
The outcomes assessed were: the demographic characteristics of the patient cohort; tumour characteristics (i.e. the number and size of metastases); the mortality and morbidity after resection, laparotomy and RF ablation; the length of stay; the probability of tumour necrosis with RF; the detection thresholds associated with different imaging techniques;
survival; the hazard rates; and quality of life decrements.
Study designs and other criteria for inclusion in the review
The authors stated that a comprehensive review of the English-language literature was undertaken to identify primary studies. However, limited information on the design and other characteristics of the primary studies was provided. Some data came from US life tables.
Sources searched to identify primary studies
MEDLINE was searched for primary studies, the bibliographies of which were also checked.
Criteria used to ensure the validity of primary studies
Not stated.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Approximately 30 references provided clinical data.
Methods of combining primary studies
The primary estimates appear to have been combined using a narrative method.
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Investigation of differences between primary studies
Results of the review
Some of the clinical data derived from the literature are reported here.
The tumour volume doubling time was 155 days (range: 78 -233).
The normal liver volume was 1,225 cm3.
Mortality was 5% (alternative value 10%) after resection and 0.3% after RF ablation.
Morbidity was 20% after resection, 4% after laparotomy and 2% after RF ablation.
The length of stay was 12 days after resection and 5 days after laparotomy.
The additional length of stay after resection complications, laparotomy complications, or RF ablation complications was 3 days in each case.
The probability of complete tumour necrosis with RF was 0.784 (alternative value 1) for tumours =/< 2.5 cm, 0.472 (range: 0.75 -1) for rumours >2.5 to 4 cm, and 0.316 (range: 0.5 -1) for tumours >4 to 10 cm.
The sensitivity of computed tomography (CT) was 0.85 (alternative value 0.75).
The detection threshold was 0.5 cm (alternative value 1.0 cm) at CT and 0.3 cm (alternative value 0.5 cm) at intraoperative ultrasound (US).
The hazard rate was 0.7427 when less than 25% of liver volume was replaced by tumour (LVRT) and 1.3203 when at least 25% LVRT.
Patients with less than 25% (but more than 0%) LVRT were assigned a median survival of 11.5 months, while patients with LVRT of 25% or more had a median survival of 6.3 months.
In patients with metastatic CRC, quality of life declines rapidly at the end of life (median time for decline: last 12 days of life). Hence, quality-adjusted life years (QALYs) were estimated by subtracting a toll in the final cycle (month) before death, estimating that quality of life in the month prior to death was 60% of that for age-and gender-matched controls. QALY tolls were also assessed to account for decreased quality of life following RF ablation, hepatic resection, or laparotomy.
Methods used to derive estimates of effectiveness
The authors made some assumptions to derive clinical data that were not available from the literature.
Estimates of effectiveness and key assumptions
The mortality after laparotomy was 1%. No new liver metastases developed over time, as all patients were assumed to have undergone removal of their primary tumours. Each metastasis had an independent and equal probability of being located in each of the eight liver segments. Other assumptions were also made in the model.
Measure of benefits used in the economic analysis
The summary benefit measure used was the number of QALYs. This was obtained by combining expected survival and the utility weights derived from the literature. An annual discount rate of 3% was applied.
it was not possible to assess the validity of the primary estimates. The methods used to extract the data from the primary studies and to combine the clinical estimates were not described. Some opinions were also used to derive clinical data because of the lack of published evidence. Sensitivity analyses were performed to assess the robustness of the final cost-effectiveness estimates to variations in the clinical data.
Validity of estimate of measure of benefit
The benefit measure used in the analysis was appropriate, as QALYs capture the impact of the interventions on the most relevant dimensions of care (i.e. survival and quality of life) for patients with CRC. Further, QALYs are comparable with the benefits of other health care interventions. Discounting was applied in accordance with US guidelines for economic evaluations. Some details on the source of the utility weights and the approach used to calculate QALYs were provided.
Validity of estimate of costs
The choice of adopting a societal perspective in the analysis was appropriate as all the costs were included in the analysis. The costs were presented as macro-categories and a detailed breakdown of the cost items was not reported. This might limit the possibility of replicating the analysis in other settings, but it is quite common when the long-term costs of cancer care are assessed. The source of the data was reported for all costs, but information on resource use was mainly based on authors' opinions. No statistical analyses of the costs were performed, but the issue of uncertainty in resource consumption and cost estimates was extensively addressed in the sensitivity analysis. Discounting was appropriately performed and the impact of variations in the discount rate was investigated. The price year was reported, which will facilitate reflation exercises in other settings.
